Literature DB >> 31486858

[Respiratory syncytial virus].

Jürgen Seidenberg1.   

Abstract

Respiratory syncytial virus (RSV) is worldwide a very important virus leading to infection of the respiratory system. In particular preterm babies, infants and elderly adults are prone to developing severe diseases such as bronchiolitis or pneumonia, which require intensive care and cause increased mortality. Although RSV is rapidly detected, preventive and therapeutic measures are limited. New antivirals are already in clinical trials.

Entities:  

Keywords:  Antiviral agents; Bronchiolitis; Pneumonia; Respiratory syncytial virus infections; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 31486858     DOI: 10.1007/s00108-019-00673-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  24 in total

Review 1.  Acute and long-term effects of viral bronchiolitis in infancy.

Authors:  J F Price
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis.

Authors:  Cynthia A Bonville; Helene F Rosenberg; Joseph B Domachowske
Journal:  Antiviral Res       Date:  2005-11-28       Impact factor: 5.970

3.  Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes.

Authors:  P Pilie; W A Werbel; J Riddell; X Shu; D Schaubel; K S Gregg
Journal:  Transpl Infect Dis       Date:  2015-07-06       Impact factor: 2.228

4.  Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia.

Authors:  Niclas Johansson; Mats Kalin; Jonas Hedlund
Journal:  Scand J Infect Dis       Date:  2011-04-05

5.  Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults.

Authors:  Kyle Widmer; Yuwei Zhu; John V Williams; Marie R Griffin; Kathryn M Edwards; H Keipp Talbot
Journal:  J Infect Dis       Date:  2012-04-23       Impact factor: 5.226

6.  SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Authors:  Evan J Anderson; John P DeVincenzo; Eric A F Simões; Leonard R Krilov; Michael L Forbes; Pia S Pannaraj; Claudia M Espinosa; Robert C Welliver; Leslie I Wolkoff; Ram Yogev; Paul A Checchia; Joseph B Domachowske; Natasha Halasa; Scott J McBride; Veena R Kumar; Kimmie K McLaurin; Christopher P Rizzo; Christopher S Ambrose
Journal:  Am J Perinatol       Date:  2019-04-16       Impact factor: 1.862

Review 7.  The impact of viral bronchiolitis phenotyping: Is it time to consider phenotype-specific responses to individualize pharmacological management?

Authors:  Carlos E Rodríguez-Martínez; Jose A Castro-Rodriguez; Gustavo Nino; Fabio Midulla
Journal:  Paediatr Respir Rev       Date:  2019-04-12       Impact factor: 2.726

Review 8.  Therapeutic Potential of Spirooxindoles as Antiviral Agents.

Authors:  Na Ye; Haiying Chen; Eric A Wold; Pei-Yong Shi; Jia Zhou
Journal:  ACS Infect Dis       Date:  2016-05-05       Impact factor: 5.084

9.  Characteristics of hospitalized adult patients with laboratory documented Influenza A, B and Respiratory Syncytial Virus - A single center retrospective observational study.

Authors:  Regev Cohen; Frida Babushkin; Keren Geller; Talya Finn
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

10.  A role for Streptococcus pneumoniae in virus-associated pneumonia.

Authors:  Shabir A Madhi; Keith P Klugman
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

View more
  1 in total

1.  Integrated Network Pharmacology and Lipidomics to Reveal the Inhibitory Effect of Qingfei Oral Liquid on Excessive Autophagy in RSV-Induced Lung Inflammation.

Authors:  Lili Lin; Li An; Hui Chen; Lu Feng; Mengjiang Lu; Yuling Liu; Chu Chu; Jinjun Shan; Tong Xie; Xiaorong Wang; Shouchuan Wang
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.